PIVKA-II is an abnormal form of prothrombin, a blood-clotting protein made by the liver. The name stands for “protein induced by vitamin K absence or antagonist-II.” It rises when the liver cannot fully activate prothrombin because vitamin K is lacking, blocked by a medication such as warfarin, poorly absorbed, or disrupted by certain liver conditions. The same marker is also used as des-gamma-carboxy prothrombin, or DCP, in hepatocellular carcinoma testing.
A PIVKA-II result needs context. A high value can point toward vitamin K deficiency and higher bleeding risk, but it can also occur with cholestasis, obstructive jaundice, broad-spectrum antibiotics, warfarin use, severe liver disease, or liver cancer. A normal value is reassuring in some settings, but it does not rule out every vitamin K problem or every liver tumor. The result works best when interpreted with PT, INR, liver enzymes, bilirubin, albumin, platelet count, imaging, medication history, and symptoms.
- PIVKA-II measures undercarboxylated prothrombin, an inactive clotting protein produced when vitamin K action is inadequate or abnormal.
- High PIVKA-II can mean vitamin K deficiency, especially with fat malabsorption, cholestasis, poor intake, antibiotics, or newborn vitamin K deficiency risk.
- High PIVKA-II can also be a liver cancer marker, usually reported as DCP or PIVKA-II in people at risk for hepatocellular carcinoma.
- Reference ranges depend on the assay, with common examples including less than 7.5 ng/mL for DCP or less than 40 mAU/mL for some PIVKA-II tumor marker assays.
- PT and INR may stay normal early, so PIVKA-II can detect functional vitamin K problems before standard clotting tests become abnormal.
- Urgent care is needed for abnormal bleeding, black stools, vomiting blood, severe headache, confusion, fainting, or signs of internal bleeding.
Table of Contents
- What the PIVKA-II Test Measures
- When the Test Is Ordered
- Normal Range and Result Units
- High PIVKA-II Causes
- PIVKA-II, PT, INR, and Bleeding Risk
- PIVKA-II and Liver Cancer
- Preparation and Result Factors
- Next Steps After Abnormal Results
What the PIVKA-II Test Measures
PIVKA-II measures abnormal prothrombin that has not been fully activated by vitamin K. Prothrombin is also called factor II. It helps form blood clots after injury. The liver makes prothrombin, but the protein needs a vitamin K-dependent chemical step called gamma-carboxylation before it can work properly.
When that activation step fails, the liver releases an undercarboxylated form of prothrombin. That abnormal protein is PIVKA-II. The same marker is often called des-gamma-carboxy prothrombin, or DCP, especially in liver cancer testing.
The test does not measure vitamin K itself. It measures the effect of vitamin K on a clotting protein. That difference matters because a person may have normal vitamin K intake but still have high PIVKA-II if vitamin K is not absorbed, cannot be recycled, is blocked by medicine, or cannot be used normally by damaged liver tissue.
Vitamin K is fat-soluble, so bile flow and intestinal absorption strongly affect status. When bile cannot reach the intestine well, as in cholestasis or bile duct obstruction, absorption of vitamin K can fall. Over time, the liver may make more undercarboxylated clotting proteins, and PIVKA-II may rise.
PIVKA-II also has a second major clinical use: hepatocellular carcinoma, the most common primary liver cancer. Some liver cancer cells produce abnormal prothrombin even when the person is not simply vitamin K deficient. In that setting, the test is used as a tumor marker, often alongside alpha-fetoprotein, liver imaging, and other risk information.
PIVKA-II is most useful when the clinician is asking a focused question, such as:
- Is vitamin K action reduced even though PT or INR is still normal?
- Is cholestatic liver disease causing fat-soluble vitamin malabsorption?
- Is a person on a vitamin K antagonist producing the expected abnormal prothrombin?
- Does a person with chronic liver disease need more evaluation for hepatocellular carcinoma?
- Is a known liver cancer marker falling or rising after treatment?
The answer depends on the patient group. A high PIVKA-II in a child with cholestasis points strongly toward functional vitamin K deficiency. A high DCP in an adult with cirrhosis raises a different concern, especially if imaging or AFP is abnormal. A high result in a person taking warfarin may reflect the drug’s intended effect rather than a new disease.
For a broader look at direct vitamin K testing, the vitamin K blood test may be considered in some settings, although PIVKA-II often gives more functional information about clotting protein activation.
When the Test Is Ordered
Clinicians order PIVKA-II when they need evidence of impaired vitamin K-dependent clotting or when they are evaluating risk for hepatocellular carcinoma. It is not part of a standard annual blood panel. It is usually a targeted test.
In vitamin K deficiency workups, PIVKA-II may be ordered when standard clotting tests do not fully explain the clinical picture. PT and INR usually become abnormal when vitamin K deficiency is more pronounced, but PIVKA-II can rise earlier. This is why it is sometimes described as a sensitive marker of subclinical vitamin K deficiency.
PIVKA-II may be useful when a person has:
- Cholestatic liver disease
- Bile duct obstruction or prolonged jaundice
- Cystic fibrosis, short bowel syndrome, celiac disease, inflammatory bowel disease, or another malabsorption condition
- Poor intake, prolonged fasting, or severe illness
- Long courses of broad-spectrum antibiotics
- Newborn or infant risk factors for vitamin K deficiency bleeding
- Unexplained bruising or bleeding with concern for clotting factor activation problems
- Abnormal PT or INR when vitamin K deficiency is suspected
In liver disease, PIVKA-II can help separate several overlapping issues. A person with chronic liver disease may have poor liver synthetic function, cholestasis-related vitamin K malabsorption, low platelets from portal hypertension, or liver cancer risk. One abnormal clotting result cannot sort all of this out. PIVKA-II adds another clue by showing whether abnormal prothrombin production is present.
The test may also be ordered in hepatocellular carcinoma evaluation. In that setting, it is often used with liver ultrasound, CT, MRI, AFP, AFP-L3, and clinical risk factors. It may help with risk assessment, diagnosis support, prognosis, and post-treatment monitoring when it was elevated before treatment.
PIVKA-II should not be used alone to diagnose liver cancer. Some people with hepatocellular carcinoma have normal PIVKA-II. Some people without cancer have high PIVKA-II because of vitamin K deficiency, warfarin use, cholestasis, obstructive jaundice, or antibiotics. The marker is helpful, but it is not specific enough to stand by itself.
In everyday practice, a clinician may order PIVKA-II together with tests such as PT, INR, bilirubin, AST, ALT, alkaline phosphatase, GGT, albumin, platelet count, and imaging. A liver function tests panel helps show whether the liver pattern looks more like hepatocellular injury, cholestasis, impaired protein synthesis, or a mixed process.
Normal Range and Result Units
PIVKA-II reference ranges vary because laboratories use different assays, sample types, antibodies, calibration systems, and units. Always compare the result with the reference interval printed on the report.
The two most common reporting styles are ng/mL and mAU/mL. DCP tumor marker assays may use ng/mL, while many PIVKA-II immunoassays use mAU/mL. These units are not interchangeable. A result of 40 mAU/mL does not equal 40 ng/mL.
| Reporting style | Common example of a normal cutoff | Common use | Important limitation |
|---|---|---|---|
| DCP in ng/mL | Less than 7.5 ng/mL in some laboratories | Hepatocellular carcinoma risk assessment or monitoring | Cutoffs differ by laboratory and clinical setting |
| PIVKA-II in mAU/mL | Less than 40 mAU/mL in some tumor marker assays | HCC evaluation, recurrence monitoring, or cancer-risk stratification | Not the same scale as ng/mL testing |
| PIVKA-II in ng/mL for vitamin K status | Cutoffs such as greater than 2 or 3 ng/mL have been used in studies or specific labs | Functional vitamin K deficiency assessment | Study cutoffs may not match a clinical lab report |
A normal result usually means there is no measurable excess of undercarboxylated prothrombin by that assay. In a vitamin K deficiency evaluation, this makes significant functional deficiency less likely, especially if PT, INR, and bleeding history are also normal.
A high result means abnormal prothrombin is present. It does not automatically identify the cause. The same high result could reflect vitamin K deficiency, vitamin K antagonism, cholestasis, liver cancer, or more than one factor at once.
Mild elevations can be difficult to interpret. A small increase in a person with poor diet and recent antibiotics may be handled differently from a small increase in a person with cirrhosis and a new liver lesion. Trends also matter. A value that is rising over time may be more concerning than a stable borderline result, especially in liver cancer monitoring.
Large elevations often deserve more urgent attention, but the urgency still depends on symptoms and other tests. A high PIVKA-II plus prolonged PT/INR suggests impaired vitamin K-dependent clotting. A high PIVKA-II plus jaundice, pale stools, dark urine, and high direct bilirubin suggests cholestasis or bile duct obstruction. A high PIVKA-II plus cirrhosis and abnormal imaging raises concern for hepatocellular carcinoma.
A low PIVKA-II result usually has no special clinical meaning. Unlike many nutrients, this is not a “higher is better” marker. The desired result is usually low or undetectable abnormal prothrombin.
When comparing repeat results, use the same laboratory whenever possible. Switching from one assay platform to another can make trends hard to read, especially when values are near the cutoff.
High PIVKA-II Causes
High PIVKA-II means the body is producing measurable abnormal prothrombin. The most common causes fall into several groups: vitamin K deficiency, impaired absorption, medication effects, liver and bile duct disease, and hepatocellular carcinoma.
Vitamin K deficiency or poor vitamin K effect
Vitamin K deficiency is a leading reason PIVKA-II rises. The liver needs vitamin K to activate clotting factors II, VII, IX, and X, as well as proteins C and S. When vitamin K supply or recycling drops, undercarboxylated proteins increase.
Common reasons include low intake, prolonged poor appetite, restrictive diets, severe illness, prolonged fasting, and malnutrition. Diet alone rarely causes severe deficiency in a healthy adult, but it can contribute when combined with antibiotics, fat malabsorption, liver disease, or poor overall nutrition.
Vitamin K1, also called phylloquinone, comes mainly from green leafy vegetables and plant oils. A vitamin K1 test measures circulating phylloquinone, but it can change with recent intake and does not always reflect clotting protein activation as directly as PIVKA-II.
Cholestasis and fat malabsorption
Cholestasis is one of the strongest clinical settings for high PIVKA-II. Bile helps absorb fat-soluble vitamins, including vitamins A, D, E, and K. When bile flow is reduced, vitamin K absorption may fall even if the diet contains enough vitamin K.
This can happen with biliary atresia, primary sclerosing cholangitis, primary biliary cholangitis, bile duct stones, pancreatic or bile duct tumors, drug-induced cholestasis, and other causes of obstructive jaundice. In children with cholestatic liver disease, PIVKA-II can be high even when PT is still normal, which makes it useful for early detection of functional deficiency.
The same cholestatic pattern often affects other fat-soluble vitamins. Low vitamin D, low vitamin A, and low vitamin E may appear alongside high PIVKA-II. A high alkaline phosphatase and GGT pattern may point toward bile duct involvement, while direct bilirubin can rise when bile flow is blocked.
Warfarin and other vitamin K antagonists
Warfarin blocks vitamin K recycling. That is how it reduces clotting activity. A high PIVKA-II in someone taking warfarin may reflect the medication effect rather than nutritional deficiency.
This point is important because warfarin patients should not change vitamin K intake or take vitamin K supplements without medical guidance. Sudden changes can shift INR and alter anticoagulation control. Direct oral anticoagulants, such as apixaban or rivaroxaban, do not work by blocking vitamin K and should not raise PIVKA-II in the same expected way.
Some rodenticides, especially long-acting anticoagulant poisons, also block vitamin K recycling and can cause severe bleeding. Suspected poisoning needs urgent medical care.
Antibiotics and disrupted gut flora
Broad-spectrum antibiotics can contribute to vitamin K deficiency in vulnerable people. Gut bacteria produce menaquinones, forms of vitamin K2. Antibiotics can reduce that contribution. This usually matters most when combined with poor intake, critical illness, liver disease, fat malabsorption, or prolonged therapy.
A short antibiotic course in a well-nourished adult usually does not cause major vitamin K deficiency. A long course in a hospitalized patient with poor intake can be different.
Hepatocellular carcinoma
Hepatocellular carcinoma can raise PIVKA-II or DCP because malignant hepatocytes may release abnormal prothrombin. This is not simply a nutrition issue. In HCC, PIVKA-II may reflect tumor biology, including tumor size, vascular invasion risk, recurrence risk, and treatment response in some studies.
A high value in someone with cirrhosis, chronic hepatitis B, chronic hepatitis C, alcohol-related liver disease, or metabolic dysfunction-associated steatotic liver disease needs careful evaluation. It should be interpreted with imaging and other tumor markers, not treated as proof of cancer by itself.
PIVKA-II, PT, INR, and Bleeding Risk
PIVKA-II can rise before PT and INR become abnormal. This is one of its main strengths in vitamin K deficiency evaluation.
PT, or prothrombin time, measures how long plasma takes to clot through the extrinsic and common clotting pathways. INR standardizes PT results, especially for warfarin monitoring. These tests reflect clotting function, while PIVKA-II reflects production of abnormal vitamin K-dependent prothrombin. The tests overlap, but they do not measure the same thing.
A person can have high PIVKA-II with normal PT and INR when deficiency is early, mild, or partially compensated. This pattern can appear in cholestatic liver disease and in some children receiving vitamin K supplementation that is not fully correcting the problem.
A person can also have high PIVKA-II with prolonged PT and INR. That pattern is more concerning for clinically important impairment of vitamin K-dependent clotting, especially if there are bleeding symptoms. A prothrombin time test and an INR blood test help determine whether the abnormal prothrombin is affecting clotting time.
| Pattern | Common meaning | Typical follow-up |
|---|---|---|
| Normal PIVKA-II, normal PT/INR | No clear evidence of functional vitamin K-related clotting impairment | Review symptoms, diet, medications, and reason for testing |
| High PIVKA-II, normal PT/INR | Possible early or subclinical vitamin K deficiency, cholestasis, medication effect, or HCC marker elevation | Check liver and bile markers, medication history, and repeat or image if indicated |
| High PIVKA-II, high PT/INR | More significant vitamin K effect, warfarin effect, malabsorption, liver synthetic problem, or mixed cause | Assess bleeding risk promptly and treat the cause |
| Normal PIVKA-II, high PT/INR | Cause may not be vitamin K deficiency; consider liver failure, factor deficiency, anticoagulants, or lab issue | Further coagulation testing and clinical review |
Bleeding risk does not depend on PIVKA-II alone. It depends on clotting factor activity, platelet count and function, fibrinogen, vessel health, liver function, kidney function, medications, and the type of procedure or injury. A person with high PIVKA-II and normal clotting times may not be actively bleeding, but the result can still identify a risk that should be corrected before surgery or an invasive procedure.
Symptoms that deserve prompt medical attention include frequent nosebleeds, bleeding gums, heavy menstrual bleeding, blood in urine, black or tarry stools, vomiting blood, large unexplained bruises, prolonged bleeding from small cuts, severe headache, confusion, weakness on one side, or fainting. In infants, poor feeding, unusual sleepiness, bulging fontanelle, seizures, pallor, bruising, or bleeding from the umbilical stump can be emergency signs.
A broader coagulation panel may be needed when bleeding risk is unclear, especially before procedures, during liver disease evaluation, or when anticoagulant exposure is possible.
PIVKA-II and Liver Cancer
PIVKA-II is also a tumor marker for hepatocellular carcinoma. In this setting, it is often reported as DCP. It may be used with AFP, AFP-L3, ultrasound, CT, MRI, and clinical risk factors.
HCC usually develops in people with chronic liver injury or cirrhosis, although it can also occur without cirrhosis, especially in chronic hepatitis B. Risk is higher with cirrhosis from hepatitis B, hepatitis C, alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, hemochromatosis, and some inherited or autoimmune liver diseases.
Routine surveillance for high-risk patients commonly uses ultrasound every 6 months, often with AFP depending on the guideline and setting. PIVKA-II is widely used in some countries and increasingly studied elsewhere, but it is not a universal replacement for imaging.
PIVKA-II can add value because it reflects different biology than AFP. AFP may rise with some liver cancers, pregnancy, germ cell tumors, and active liver regeneration. PIVKA-II tends to be more linked to abnormal prothrombin production by malignant liver cells and may correlate with features such as tumor burden or vascular invasion in some studies. When AFP is normal, PIVKA-II may still be abnormal in some patients with HCC.
Still, false positives happen. Obstructive jaundice, cholestasis, warfarin, and vitamin K deficiency can raise PIVKA-II without cancer. False negatives also happen. A normal DCP or PIVKA-II result does not rule out HCC, and some laboratories note that a substantial minority of people with HCC have values within the reference range.
The result is most useful when interpreted as part of a pattern:
- Rising PIVKA-II in a person with cirrhosis may increase concern, especially with a liver lesion.
- High PIVKA-II with high AFP may strengthen suspicion, but imaging still drives diagnosis.
- Falling PIVKA-II after HCC treatment may suggest response if it was high before treatment.
- Rising PIVKA-II after resection, ablation, transplant, or locoregional therapy may prompt evaluation for recurrence.
- High PIVKA-II during obstructive jaundice may need reassessment after the bile duct problem and vitamin K status are corrected.
Some biomarker models combine age, sex, AFP, AFP-L3, and DCP/PIVKA-II to estimate HCC probability. These models can perform well in research and selected clinical settings, but their use depends on local guidelines, assay availability, and patient population.
PIVKA-II should never delay imaging when HCC is suspected. A liver lesion, rising AFP, new decompensation, unexplained weight loss, worsening jaundice, or portal vein thrombosis needs proper liver imaging and specialist review.
Preparation and Result Factors
Most PIVKA-II blood tests do not require fasting, but preparation depends on the laboratory and the reason for testing. Follow the ordering clinician’s instructions, especially if the test is part of a larger panel.
Do not stop warfarin, antibiotics, seizure medicines, supplements, or prescribed vitamin K unless the clinician tells you to. Medication changes can affect bleeding or clotting risk. For warfarin users, vitamin K intake should usually stay consistent rather than swing sharply from very low to very high.
Tell the clinician and laboratory about:
- Warfarin or another vitamin K antagonist
- Recent vitamin K supplements or injections
- Multivitamins, prenatal vitamins, nutrition shakes, or tube feeding formulas
- Broad-spectrum antibiotics
- Anticonvulsants that may affect vitamin K metabolism
- Bile acid binders, mineral oil, or weight-loss medicines that reduce fat absorption
- Recent jaundice, pale stools, dark urine, itching, or bile duct procedures
- Pregnancy or recent childbirth
- Known liver disease, cirrhosis, hepatitis, or liver cancer
- Planned surgery, biopsy, endoscopy, dental procedure, or injection
Recent vitamin K treatment can lower PIVKA-II over time, but the speed of change varies. PT and INR may improve faster than PIVKA-II because PIVKA-II reflects abnormal protein already present in circulation. This is one reason clinicians may repeat testing rather than rely on one value after treatment.
Sample handling can also matter. Some laboratories require serum, prompt separation, freezing for longer transport, or specific tubes. Hemolysis, severe lipemia, or delays may affect certain tests. The report should include any specimen problems if they occurred.
Result interpretation becomes harder when several causes overlap. For example, a person with cirrhosis may have cholestasis, poor intake, antibiotics, and a liver nodule. A high PIVKA-II in that setting cannot be assigned to one cause without reviewing bilirubin, ALP, GGT, PT, INR, albumin, platelets, imaging, and medication exposure. A hepatic function panel can help show whether bile flow, liver cell injury, or liver protein production is abnormal.
Dietary vitamin K intake can influence deficiency risk but should not be changed drastically before testing unless instructed. Leafy greens such as kale, spinach, collards, parsley, and Swiss chard contain vitamin K1. Fermented foods and some animal foods contain vitamin K2 forms. People taking warfarin do not usually need to avoid these foods completely; consistency is more important than avoidance.
Next Steps After Abnormal Results
The right next step depends on why the test was ordered. A high PIVKA-II during a vitamin K deficiency evaluation is handled differently from a high DCP during HCC surveillance.
For suspected vitamin K deficiency, clinicians usually review diet, medications, bile flow, malabsorption risk, PT, INR, and bleeding symptoms. They may check liver enzymes, bilirubin, albumin, platelet count, fat-soluble vitamins, stool or imaging clues of malabsorption, and the response to vitamin K therapy. If PT or INR is prolonged, treatment may be more urgent.
For suspected cholestasis, follow-up often focuses on bile flow. Tests may include direct bilirubin, alkaline phosphatase, GGT, bile acids, ultrasound, MRCP, CT, or referral to gastroenterology or hepatology. Correcting vitamin K status without addressing a blocked bile duct may only partly solve the problem.
For newborns and infants, abnormal PIVKA-II needs careful attention because vitamin K deficiency bleeding can be severe. Infants with cholestasis, biliary atresia, prolonged jaundice, poor growth, or no vitamin K prophylaxis at birth need prompt pediatric evaluation. Oral vitamin K may be less reliable when bile flow is poor, so clinicians may choose parenteral routes in high-risk cases.
For people taking warfarin, an elevated PIVKA-II may be expected. INR remains the main monitoring test for warfarin intensity. Any bleeding, very high INR, medication interaction, missed doses, or diet change should be managed by the prescribing clinician.
For liver cancer evaluation, the next step is usually imaging or specialist review rather than vitamin K treatment alone. A high PIVKA-II in a person with chronic liver disease may lead to multiphasic CT, contrast MRI, repeat ultrasound, AFP testing, AFP-L3 testing, or follow-up at a liver center. If PIVKA-II was already known to be elevated before HCC treatment, repeat levels may help monitor response or recurrence, but imaging remains central.
A normal PIVKA-II may also need follow-up if symptoms or other tests are concerning. Normal PIVKA-II does not explain prolonged bleeding by itself, and it does not rule out liver cancer in a high-risk patient. The clinician may still evaluate platelet problems, fibrinogen, aPTT, inherited clotting disorders, liver synthetic function, anticoagulant exposure, or imaging findings.
A practical way to read the result is to ask four questions:
- Is there evidence of bleeding risk, such as prolonged PT/INR, symptoms, or an upcoming procedure?
- Is there evidence of poor vitamin K absorption, such as cholestasis, jaundice, bowel disease, or fat malabsorption?
- Is a medication explaining the result, especially warfarin or long antibiotic use?
- Is liver cancer risk present, such as cirrhosis, chronic hepatitis B, a liver lesion, or rising tumor markers?
A high PIVKA-II is a clue, not a final diagnosis. The safest interpretation comes from matching the number to the person’s risk factors, symptoms, medicines, and other test results.
References
- Vitamin K Deficiency in Neonates and Adults 2026 (Review)
- DCP – Overview: Des-Gamma-Carboxy Prothrombin, Serum 2026 (Laboratory Reference)
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma 2023 (Guideline)
- Vitamin K deficiency bleeding in children with cholestatic liver disease: a systematic review and meta-analysis 2025 (Systematic Review)
- Meta-analysis of the GALAD model for diagnosing primary hepatocellular carcinoma 2024 (Meta-Analysis)
- Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study 2024 (Cohort Study)
Disclaimer
PIVKA-II results should be interpreted by a qualified clinician because vitamin K deficiency, medication effects, cholestasis, liver failure, and liver cancer can produce overlapping patterns. Do not start or stop vitamin K, warfarin, antibiotics, or anticoagulants based only on this test result. Seek urgent care for active bleeding, black stools, vomiting blood, severe headache, confusion, fainting, or concerning symptoms in an infant.
